Clin2
NCT05208190Possibly a fitRecruiting

Clozapine to prevent violence in schizophrenia

SchizophreniaSchizoaffective Disorder

Treatments studied

Part of Mental health clinical trials.

This trial tests whether clozapine can reduce repeat violent behavior in people with schizophrenia or schizoaffective disorder. Participants are randomly assigned to clozapine or usual care to see which approach works better for preventing violence.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
280 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You have a diagnosis of schizophrenia or schizoaffective disorder confirmed by a structured interview
  • You had a minor or serious act of violence in the last 6 months
  • You can give informed consent and your clinician says you are medically stable for study treatment
  • Your current treatment situation allows you to be eligible for either clozapine or usual care (with specific medication timing rules)
  • You do not have major unstable medical or neurological conditions, especially serious bone-marrow problems
  • You are not allergic or unable to take clozapine before

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07227818Recruiting· Phase 3
Testing NBI-1117568 to prevent schizophrenia relapse

This trial tests a new medicine, NBI-1117568, to see if it can help prevent a relapse of schizophrenia symptoms. It is for adults who have been stable on other antipsychotics and want to avoid returning to the hospital for a psychiatric stay.

Garden Grove, California
NCT05025605Recruiting· Phase 1
Study medicine for agitation in youth with bipolar or schizophrenia

This Phase 1 trial tests whether BXCL501 is safe and can help reduce agitation in children and teens who have bipolar disorder or schizophrenia. You may be considered if your agitation is significant during screening, but certain recent medication and health factors can make you ineligible.

Anaheim, California
NCT04580134Recruiting· Phase 4
Clozapine study for people with a specific schizophrenia or bipolar type

This trial tests whether clozapine works better for people whose illness fits a specific “biotype-1” pattern. It may help reduce ongoing symptoms, but it also requires close safety monitoring.

Hartford, Connecticut
NCT05316883Recruiting· Phase 4
Testing blood markers in people on clozapine for schizophrenia

This study looks at “biomarkers,” or blood measures, in people with schizophrenia who respond to clozapine. It may help researchers understand who benefits from clozapine and why, by linking test results to symptom changes.

Glostrup Municipality, Denmark
NCT06174116Recruiting· Phase 4
Adding lumateperone to clozapine for schizophrenia

This trial tests whether adding lumateperone, an antipsychotic medication, to clozapine can improve metabolic health in people with schizophrenia. It aims to see if this combination helps with weight, blood sugar, and cholesterol levels.

Worcester, Massachusetts
NCT02639702Recruiting· Phase 4
Switching from twice-daily to once-daily clozapine for schizophrenia

This trial tests whether taking clozapine once a day (instead of twice a day) works safely for people with schizophrenia. It may help by simplifying your dosing schedule while closely monitoring your wellbeing.

Toronto, Ontario

Hear when a new Schizophrenia trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.